[1]郝吉庆,孙耕耘,沈玉先.氯美昔布抗肺癌细胞增殖作用的机制探讨[J].中国药理学通报,2009,(07):0.
 HAO Ji qing,SUN Geng yun,SHEN Yu xian.Mechanisms of lumiracoxib on antitumor in human lung cancer cells[J].Chinese Pharmacological Bulletin,2009,(07):0.
点击复制

氯美昔布抗肺癌细胞增殖作用的机制探讨()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2009年07期
页码:
0
栏目:
论著
出版日期:
2009-07-25

文章信息/Info

Title:
Mechanisms of lumiracoxib on antitumor in human lung cancer cells
作者:
郝吉庆1孙耕耘2沈玉先3
安徽医科大学第一附属医院1.肿瘤内科、2.呼吸内科,安徽 合肥230022;3.教育部重要遗传疾病基因资源利用重点实验室, 安徽 合肥230032
Author(s):
HAO Jiqing1SUN Gengyun2SHEN Yuxian3
1.Dept of Oncology,2.Dept of Pulmonary Disease,the First Affiliated Hospital of Anhui Medical University,Hefei230022,China;3.Key Laboratory of Gene Resource Utilization for Genetic Diseases of Ministry of Education and Anhui Province,Hefei230032,China
关键词:
氯美昔布肺癌COX2前列腺素E2cAMP细胞增殖
Keywords:
lumiracoxibcancer of lungcyclooxygenase2prostaglandin E2cyclic AMPproliferation
分类号:
R 329.24;R 73351;R 734.202.2
文献标志码:
A
摘要:
目的探讨氯美昔布(lumiracoxib,LUM)抗肺癌作用的可能机制。方法采用Western blot法检测不同浓度的LUM作用于A549和NCIH460细胞COX2表达及放射免疫法(RIA)检测PGE2及cAMP水平。结果A549细胞中随着LUM浓度的增加,COX2的表达水平逐渐下降。而NCIH460细胞中不同剂量组间COX2的表达水平并无明显的变化。不同浓度的LUM作用于A549和NCIH460细胞后,发现PGE2的水平下降、cAMP的水平升高均呈剂量依赖性(P<001)。结论LUM在体外的抗肺癌细胞增殖作用机制可能涉及到 COX2依赖性和非依赖性两种途径,并通过PGE2的合成减少和cAMP的水平升高来实现的。
Abstract:
AimTo investigate the possible mechanism of antitumor in human lung cancer cell lines A549 and NCIH460 induced by lumiracoxib.MethodsThe expression of COX2 was detected by Western blot and the levels of PGE2 and cAMP was determined by radioimmunoassay (RIA).ResultsCOX2 protein was highly expressed in A549 and NCIH460 cells.After treatment with 15240 μmol·L-1 LUM for 24 hrs,LUM significantly decreased the level of COX2 in A549 cells, but not in NCIH460 cells.Compared with the control, the PGE2 production was reduced and the level of cAMP was increased after the treatment with 15,30,60,120,240 μmol·L-1 of LUM, respectively.ConclusionThe effect of Lumiracoxib on antitumor is in COX2dependent orindependent manner. The antitumor effect of LUM may be related to inhibiting the COX2 activities by decreasing its secretion, upregulating the level of cAMP,and downregulating the level of PGE2.

参考文献/References:

[1]Esser R,Berry C,Du Z,et al. Preclinical pharmacology of lumiracoxib:a novel selective inhibitor of cyclooxygenase2[J].Br J Pharmacol,2005,144(4):538-50.
[2]安富荣,曹惠明.第二代环氧酶2特异性抑制剂的研究进展[J].药学服务与研究,2004,4(2):173-7.
[2]An F R,Cao H M.The second generation of cyclooxygenase2 specific inhibitors[J].Pharmace Care Res,2004,4(2):173-7.
[3]Hao J Q,Li Q,Xu S P,et al.Effect of lumiracoxib on proliferation and apoptosis of human nonsmall cell lung cancer cells in vitro[J].Chin Med J,2008,121(7):602-7.
[4]Laga A C,Zander D S,Cagle P T.Prognostic significance of cyclooxygenase 2 expression in 259 cases of nonsmall cell lung cancer[J].Arch Pathol Lab Med,2005,129(9):1113-7.
[5]Castelao J E,Bart R D 3rd, DiPerna C A,et al.Lung cancer and cyclooxygenase2[J].Ann Thorac Surg,2003,76(4):1327-35.
[6]Kim H S,Youm H R,Lee J S,et al.Correlation between cyclooxygenase2 and tumor angiogenesis in nonsmall cell lung cancer[J].Lung Cancer,2003,42(2):163-70.
[7]Toyoshima T,Kamijo R,Takizawa K,et al.Inhibitor of cyclooxygenase2 induces cellcycle arrest in the epithelial cancer cell line via upregulation of cyclin dependent kinase inhibitor P21[J].Br J Cancer,2002,86(7):1150-6.
[8]Wick M,Hurteau G,Dessev C,et al.Peroxisome proliferatoractivated receptorgamma is a target of nonsteroidal antiinflammatory drugs mediating cyclooxygenaseindependent inhibition of lung cancer cell growth[J].Mol Pharmacol,2002,62(5):1207-14.
[9]何义富,金娟,魏伟.环氧化酶2催化的前列腺素信号在肝细胞癌中作用[J].中国药理学通报,2008,24(5):561-4.
[9]He Y F,Jin J,Wei W.COX2derived prostaglandin signaling in hepatocellular carcinoma[J].Chin Pharmacol Bull,2008,24(5):561-4.
[10]Williams C S,Smalley W,DuBois R N.Aspirin use and potential mechanisms for colorectal cancer prevention[J].J Clin Invest,1997,100(6):1325-9.
[11]Lemieux L I,Rahal S S,Kennedy C R.PGE2 reduces arachidonic acid release in murine podocytes: evidence for an autocrine feedback loop[J].Am J Physiol Cell Physiol,2003,284(2):C302-9.
[12]Lin J,Hsiao P W,Chiu T H,Chao J I.Combination of cyclooxygenase2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells[J].Biochem Pharmacol,2005,70(5):658-67.
[13]陈丽昆,何友兼,黄河,等.选择性COX2抑制剂对非小细胞肺癌细胞株毒性及分子机制的研究[J].中华肿瘤防治杂志,2007,14(12):901-4.
[13]Chen L K,He Y J,Huang H,et al.Toxicity of selective COX2 inhibitor celecoxib on nonsmall cell lung cancer cell lines and the molecular mechanism in vitro[J].Chin J Cancer Prev Treat,2007,14(12):901-4.

相似文献/References:

[1]冯文彬,潘雪刁,周捷,等.利用肺癌特异性结合多肽ZS6筛选肺癌相关标志物[J].中国药理学通报,2010,(01):44.
 FENG Wen bin,PAN Xue diao,ZHOU Jie,et al.Screening of tumor mark for the lung cancer by using peptide ZS6[J].Chinese Pharmacological Bulletin,2010,(07):44.
[2]刘华钢,秦三海,刘丽敏,等.鹅掌楸碱银配合物体外诱导肺癌SPCA1细胞凋亡及其机制的研究[J].中国药理学通报,2008,(11):0.
 LIU Hua gang,QIN San hai,LIU Li min,et al.Apoptosisinducing effects of AgLA2 on SPCA1 cells and its mechanism in vitro[J].Chinese Pharmacological Bulletin,2008,(07):0.
[3]石磊,潘雪刁,王军业,等.噬菌体随机肽库淘选肺癌细胞NCIH1299特异性结合多肽[J].中国药理学通报,2009,(03):0.
 SHI Lei,PAN Xue diao,WANG Jun ye,et al.Panning and identification of lung cancer cell line NCIH1299 specific peptide from a phage display peptide library[J].Chinese Pharmacological Bulletin,2009,(07):0.
[4]彭蕾,薛仁宇,顾振纶,等.冬凌草甲素对人肺腺癌细胞株SPCA1增殖和凋亡的影响[J].中国药理学通报,2010,(04):558.
 PENG Lei,XUE Ren yu,GU Zhen lun,et al.The inhibitory and apoptosis effect of Oridonin on human lung adenocarcinoma SPCA1[J].Chinese Pharmacological Bulletin,2010,(07):558.
[5]熊飞,詹瑧,唐于平,等.PI3K/Akt信号转导通路在非小细胞肺癌中的作用[J].中国药理学通报,2010,(10):1264.
 XIONG Fei,ZHAN Zhen,TANG Yu ping,et al.The effect of PI3K/Akt signal transduction pathway in nonsmall cell lung cancer[J].Chinese Pharmacological Bulletin,2010,(07):1264.
[6]潘 峰,田 静,张旭超,等.舒尼替尼对EGFR TKI抵抗的A549 细胞株增殖抑制作用及机制研究[J].中国药理学通报,2011,(08):1121.
 PAN Feng,TIAN Jing,ZHANG Xu-chao,et al. Inhibitory effect of sunitinib on EGFR TK Iˉresistant hum an nonˉsm all cell lung cancer cell line A549and itsm echanism[J].Chinese Pharmacological Bulletin,2011,(07):1121.
[7]李济元,王卫华,张彦梅,等.白藜芦醇对肺腺癌细胞增殖和CXCR4表达的影响[J].中国药理学通报,2012,(04):588.
 LI Ji yuan,WANG Wei hua,ZHANG Yan mei,et al.Effects of resveratrol on proliferation and expression of CXCR4 in human lung adenocarcinoma A549 cells[J].Chinese Pharmacological Bulletin,2012,(07):588.
[8]潘雪刁,何冰,王桂香,等.肺癌特异性结合多肽的体外筛选和鉴定[J].中国药理学通报,2013,(03):342.
 PAN Xue diao,HE Bing,WANG Gui xiang,et al.Screening and identifying the peptide specifically binding to lung cancer by using phage display in vitro[J].Chinese Pharmacological Bulletin,2013,(07):342.
[9]韩冬,王贵佐,李满祥.腺苷酸活化蛋白激酶在肺部疾病中的作用[J].中国药理学通报,2013,(04):460.
 HAN Dong,WANG Gui zuo,LI Man xiang.Role of AMPK in pulmonary diseases[J].Chinese Pharmacological Bulletin,2013,(07):460.
[10]李梦姣,等.蓝萼甲素对人肺癌A549细胞的作用及其机制[J].中国药理学通报,2013,(06):882.
 LI Meng jiao,GU Zhen lun,DONG Li xia,et al.Effects of glaucocalyxin A on human lung cancer A549 cells and its mechanism[J].Chinese Pharmacological Bulletin,2013,(07):882.

备注/Memo

备注/Memo:
收稿日期:2009-02-06,修回日期:2009-04-23基金项目:安徽省教育厅自然科学研究项目省级一般资助项目(No KJ2007B142);安徽省科技厅科研计划资助项目(No 07021008)作者简介:郝吉庆(1969-),女,博士,副教授,副主任医师,硕士生导师,Tel:05512922987,Email:ayfy_hjq@163.com
更新日期/Last Update: 2009-07-25